A Phase 3 Trial in Metastatic Untreated Renal Cell (Kidney) Cancer [Nivolumab and Ipilimumab Followed by Nivolumab vs. Cabozantinib with Nivolumab]

This study is being done to answer the following question: Can we prolong life for patients with advanced kidney cancer, by adding a drug called cabozantinib to another treatment after receiving the standard treatment? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your advanced kidney cancer. The usual approach is defined as care most people get for advanced kidney cancer.